FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2549083453> ?p ?o ?g. }

• W2549083453 abstract "Background Antiphospholipid syndrome (APS) is defined by the presence of thrombosis and/or pregnancy morbidity in combination with the persistent positivity of antiphospholipid antibodies (aPL): lupus anticoagulant (LA), anticardiolipin (aCL) and anti b2glycoprotein I antibodies (anti-b2GPI). These autoantibodies could be detected in other pathological conditions, such as autoimmune diseases (i.e. Systemic Lupus Erythematosus - SLE -), infectious diseases or cancer. Moreover, aPL could be identified in asymptomatic subjects (aPL carriers). Concerning this group, several questions are still unsolved, such as the risk of developing thrombotic events and the need of a prophylactic treatment. To date, the aPL carriers who are considered at higher risk of thrombosis are those with LA positivity, with triple positivity (LA+aCL+anti-β2GPI) and those with persistently positive aCL at high/medium titer. Data from the literature reported a risk ranging from 0 to 3.8% after a mean follow-up period of 2.3–8.7 years. It should be considered that 70% of the evaluated aPL carriers showed a concomitant autoimmune disease, which represents a risk factor for thrombotic events. Objectives In this prospective study, we evaluated a cohort of aPL positive healthy subjects, in order to define the risk of developing thrombotic events, in comparison with a group of primary APS (PAPS) patients. Methods In this longitudinal study, we consecutively enrolled 29 aPL carriers (M/F 3/26; mean age±SD 45.0±10.9 years) and 21 PAPS (M/F 5/16; mean age±SD 41.8±12.1 years). According with the study protocol, all patients underwent clinical assessment (collection of anamnestic data and traditional risk factors for cardiovascular disease) and laboratory evaluation (aCL, anti-β2GPI, LA, antinuclear antibody – ANA –, C3 and C4 serum levels; thrombophilic screening). Data concerning the familial cardiovascular history were collected. All subjects were evaluated every 6 months. Results The comparison between aPL carriers and PAPS patients demonstrated as LA was significantly more frequent in aPL carriers (P=0.0001) while a similar percentage of triple positive patients was identified. Seventeen (58.6%) aPL carriers were treated with low dose aspirin (LDA), 2 (6.9%) with hydroxychloroquine. After a mean follow-up of 67.0 months (range 12–228), we identified an absolute risk to develop a thrombotic event of 0.03 (95% CI 0.001–0.238) and a relative risk of 0.7 (95% CI 0.02–6.44). In particular, a 55 years old female, treated with LDA, developed a thrombotic event after 84 months of follow-up, consisting in a minor stroke. The patient, without other risk factors, tested positive for LA and aCL at high/medium titer. Conclusions To the best of our knowledge, this is the first study specifically designed to evaluate only aPL positive healthy subjects. The longitudinal evaluation identified, after a mean follow-up higher than 5 years, an absolute risk for thrombotic events of 0.03, with a relative risk of 0.7. As suggested by the case described, the presence of multiple aPL positivity, with high/medium titer antibodies, requires particular attention. Disclosure of Interest None declared" @default.
• W2549083453 created "2016-11-30" @default.
• W2549083453 creator A5004955353 @default.
• W2549083453 creator A5016976152 @default.
• W2549083453 creator A5047455775 @default.
• W2549083453 creator A5060460432 @default.
• W2549083453 creator A5070588930 @default.
• W2549083453 creator A5079240669 @default.
• W2549083453 creator A5084835799 @default.
• W2549083453 creator A5086701427 @default.
• W2549083453 creator A5087114501 @default.
• W2549083453 creator A5087623314 @default.
• W2549083453 date "2016-06-01" @default.
• W2549083453 modified "2023-09-27" @default.
• W2549083453 title "AB0447 Anti-Phospholipid Positivity in Healthy Subjects: Evaluation of Risk for Thrombotic Event after A 5 Years Follow-Up" @default.
• W2549083453 doi "https://doi.org/10.1136/annrheumdis-2016-eular.4862" @default.
• W2549083453 hasPublicationYear "2016" @default.
• W2549083453 type Work @default.
• W2549083453 sameAs 2549083453 @default.
• W2549083453 citedByCount "0" @default.
• W2549083453 crossrefType "journal-article" @default.
• W2549083453 hasAuthorship W2549083453A5004955353 @default.
• W2549083453 hasAuthorship W2549083453A5016976152 @default.
• W2549083453 hasAuthorship W2549083453A5047455775 @default.
• W2549083453 hasAuthorship W2549083453A5060460432 @default.
• W2549083453 hasAuthorship W2549083453A5070588930 @default.
• W2549083453 hasAuthorship W2549083453A5079240669 @default.
• W2549083453 hasAuthorship W2549083453A5084835799 @default.
• W2549083453 hasAuthorship W2549083453A5086701427 @default.
• W2549083453 hasAuthorship W2549083453A5087114501 @default.
• W2549083453 hasAuthorship W2549083453A5087623314 @default.
• W2549083453 hasConcept C126322002 @default.
• W2549083453 hasConcept C137916694 @default.
• W2549083453 hasConcept C159654299 @default.
• W2549083453 hasConcept C163764329 @default.
• W2549083453 hasConcept C203014093 @default.
• W2549083453 hasConcept C2776874634 @default.
• W2549083453 hasConcept C2777910003 @default.
• W2549083453 hasConcept C2779384505 @default.
• W2549083453 hasConcept C2780022809 @default.
• W2549083453 hasConcept C2780868729 @default.
• W2549083453 hasConcept C50440223 @default.
• W2549083453 hasConcept C71924100 @default.
• W2549083453 hasConcept C72563966 @default.
• W2549083453 hasConcept C90924648 @default.
• W2549083453 hasConceptScore W2549083453C126322002 @default.
• W2549083453 hasConceptScore W2549083453C137916694 @default.
• W2549083453 hasConceptScore W2549083453C159654299 @default.
• W2549083453 hasConceptScore W2549083453C163764329 @default.
• W2549083453 hasConceptScore W2549083453C203014093 @default.
• W2549083453 hasConceptScore W2549083453C2776874634 @default.
• W2549083453 hasConceptScore W2549083453C2777910003 @default.
• W2549083453 hasConceptScore W2549083453C2779384505 @default.
• W2549083453 hasConceptScore W2549083453C2780022809 @default.
• W2549083453 hasConceptScore W2549083453C2780868729 @default.
• W2549083453 hasConceptScore W2549083453C50440223 @default.
• W2549083453 hasConceptScore W2549083453C71924100 @default.
• W2549083453 hasConceptScore W2549083453C72563966 @default.
• W2549083453 hasConceptScore W2549083453C90924648 @default.
• W2549083453 hasLocation W25490834531 @default.
• W2549083453 hasOpenAccess W2549083453 @default.
• W2549083453 hasPrimaryLocation W25490834531 @default.
• W2549083453 hasRelatedWork W1990982884 @default.
• W2549083453 hasRelatedWork W2002778161 @default.
• W2549083453 hasRelatedWork W2045711502 @default.
• W2549083453 hasRelatedWork W2050117403 @default.
• W2549083453 hasRelatedWork W2417449690 @default.
• W2549083453 hasRelatedWork W2551558938 @default.
• W2549083453 hasRelatedWork W2554805575 @default.
• W2549083453 hasRelatedWork W2734560518 @default.
• W2549083453 hasRelatedWork W2754332438 @default.
• W2549083453 hasRelatedWork W2755074909 @default.
• W2549083453 hasRelatedWork W2765713943 @default.
• W2549083453 hasRelatedWork W2799726057 @default.
• W2549083453 hasRelatedWork W2910238808 @default.
• W2549083453 hasRelatedWork W3033713755 @default.
• W2549083453 hasRelatedWork W3040990240 @default.
• W2549083453 hasRelatedWork W3136232358 @default.
• W2549083453 hasRelatedWork W3164086579 @default.
• W2549083453 hasRelatedWork W3193464553 @default.
• W2549083453 hasRelatedWork W3207660912 @default.
• W2549083453 hasRelatedWork W73309389 @default.
• W2549083453 isParatext "false" @default.
• W2549083453 isRetracted "false" @default.
• W2549083453 magId "2549083453" @default.
• W2549083453 workType "article" @default.